Intracoronary Brachytherapy for Recurrent Drug-Eluting Stent Failure.

[1]  Jeroen J. Bax,et al.  Third universal definition of myocardial infarction , 2013, Nature Reviews Cardiology.

[2]  J. Brachmann,et al.  A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. , 2012, Journal of the American College of Cardiology.

[3]  K. Kent,et al.  Clinical Outcomes and Treatment After Drug-Eluting Stent Failure: The Absence of Traditional Risk Factors for In-Stent Restenosis , 2012, Circulation. Cardiovascular interventions.

[4]  A. Kastrati,et al.  Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. , 2010, Journal of the American College of Cardiology.

[5]  D. Baim,et al.  Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program. , 2008, JACC. Cardiovascular interventions.

[6]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[7]  M. Costa.  Treatment of drug-eluting stent restenosis. , 2007, American heart journal.

[8]  P. Serruys,et al.  A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[9]  Neville Kukreja,et al.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.

[10]  K. Kent,et al.  Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis. , 2006, The American journal of cardiology.

[11]  M. Sabaté,et al.  Sirolimus-eluting stents vs brachytherapy for restenosis. , 2006, JAMA.

[12]  N. Weissman,et al.  An intravascular ultrasound analysis of the mechanisms of restenosis comparing drug-eluting stents with brachytherapy. , 2006, American Journal of Cardiology.

[13]  G. Stone,et al.  Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. , 2006, JAMA.

[14]  P. Teirstein,et al.  Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. , 2006, JAMA.

[15]  P. Teirstein,et al.  Sirolimus-eluting stents for treatment of complex bypass graft disease: insights from the SECURE registry. , 2005, The Journal of invasive cardiology.

[16]  Gregg W Stone,et al.  One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV Trial , 2004, Circulation.

[17]  K. Kent,et al.  Optimizing dosimetry with high-dose intracoronary gamma radiation (21 Gy) for patients with diffuse in-stent restenosis. , 2004, Cardiovascular revascularization medicine : including molecular interventions.

[18]  Patrick W Serruys,et al.  Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”: The R apamycin-E luting S tent E valuated A t R otterdam C ardiology H ospital (RESEARCH) Registry , 2004, Circulation.

[19]  William Wijns,et al.  Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) , 2003, The Lancet.

[20]  P. Teirstein,et al.  Long-term follow-up of patients after gamma intracoronary brachytherapy failure (from GAMMA-I, GAMMA-II, and SCRIPPS-III). , 2003, The American journal of cardiology.

[21]  Patrick W. Serruys,et al.  A randomized comparison of a sirolimus eluting stent with a standard stent for coronary revascularization , 2002 .

[22]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[23]  K. Kent,et al.  Three-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis: Original WRIST , 2001 .

[24]  C. Morillo,et al.  Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. , 2001, Journal of the American College of Cardiology.

[25]  N. Weissman,et al.  Serial Intravascular Ultrasound Assessment of the Efficacy of Intracoronary &ggr;-Radiation Therapy for Preventing Recurrence in Very Long, Diffuse, In-Stent Restenosis Lesions , 2001, Circulation.

[26]  A. Lansky,et al.  Intracoronary radiation with gamma wire inhibits recurrent in-stent restenosis. , 2001, Cardiovascular radiation medicine.

[27]  M. Leon,et al.  Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. , 2000, Journal of the American College of Cardiology.

[28]  P. Teirstein,et al.  Two-year follow-up after catheter-based radiotherapy to inhibit coronary restenosis. , 1999, Circulation.

[29]  K. Robinson,et al.  Effect of intravascular irradiation on cell proliferation, apoptosis, and vascular remodeling after balloon overstretch injury of porcine coronary arteries. , 1997, Circulation.

[30]  A. Gershlick,et al.  Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS) , 2004 .

[31]  K. Kent,et al.  Three-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis. Original WRIST. Washington Radiation for In-Stent Restenosis Trial. , 2001, Cardiovascular radiation medicine.

[32]  S. Achenbach,et al.  Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty , 2022 .